DE602005024384D1 - Neue verbindungen, ihre herstellung und verwendung - Google Patents
Neue verbindungen, ihre herstellung und verwendungInfo
- Publication number
- DE602005024384D1 DE602005024384D1 DE602005024384T DE602005024384T DE602005024384D1 DE 602005024384 D1 DE602005024384 D1 DE 602005024384D1 DE 602005024384 T DE602005024384 T DE 602005024384T DE 602005024384 T DE602005024384 T DE 602005024384T DE 602005024384 D1 DE602005024384 D1 DE 602005024384D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- diabetes
- pharmaceutical compositions
- type
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400719 | 2004-05-05 | ||
| PCT/EP2005/052014 WO2005105726A1 (en) | 2004-05-05 | 2005-05-03 | Novel compounds, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005024384D1 true DE602005024384D1 (de) | 2010-12-09 |
Family
ID=34968773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005024384T Active DE602005024384D1 (de) | 2004-05-05 | 2005-05-03 | Neue verbindungen, ihre herstellung und verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7968723B2 (de) |
| EP (1) | EP1745003B1 (de) |
| JP (1) | JP2007536343A (de) |
| AT (1) | ATE486055T1 (de) |
| DE (1) | DE602005024384D1 (de) |
| ES (1) | ES2352085T3 (de) |
| WO (1) | WO2005105726A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510024A (pt) * | 2004-05-14 | 2007-09-25 | Irm Llc | compostos e composições como modulares de ppar |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| EP2298742B1 (de) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy essigsäuren als PPAR delta Aktivatoren |
| EP1999098A2 (de) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung |
| AU2011296737A1 (en) | 2010-08-31 | 2013-04-11 | Snu R&Db Foundation | Use of the fetal reprogramming of a PPAR delta agonist |
| JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ｐｐａｒ活性化剤 |
| CN112759515B (zh) * | 2020-12-28 | 2023-06-13 | 广东药科大学 | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
| GB2279659B (en) * | 1993-07-05 | 1998-04-22 | Merck Patent Gmbh | Liquid crystalline material |
| CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
| JP2002503203A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬及び抗肥満症薬としての複素環誘導体 |
| AU719146B2 (en) | 1996-02-02 | 2000-05-04 | Merck & Co., Inc. | Antidiabetic agents |
| ES2202582T3 (es) | 1996-02-02 | 2004-04-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| ATE319440T1 (de) | 1996-12-23 | 2006-03-15 | Merck & Co Inc | Antidiabetische mittel |
| CA2295930C (en) | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
| WO1999020275A1 (en) | 1997-10-17 | 1999-04-29 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
| AR018698A1 (es) * | 1999-06-01 | 2001-11-28 | Procter & Gamble | Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU7995300A (en) | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| CN1423566A (zh) | 1999-11-10 | 2003-06-11 | 武田药品工业株式会社 | 体重增加抑制剂 |
| NZ517667A (en) | 1999-11-11 | 2004-05-28 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer |
| US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| KR20020081424A (ko) | 2000-03-09 | 2002-10-26 | 아벤티스 파마 도이칠란트 게엠베하 | Ｐｐａｒ 매개인자의 치료학적 용도 |
| US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| AU2001277723A1 (en) | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
| US6630504B2 (en) * | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2002046154A1 (en) | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Peroxisome proliferator activated receptor d activators |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US7238716B2 (en) | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
| EP1357914A2 (de) | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Verfahren zur behandlung von ppar vermittelten krankheiten |
| WO2002076957A1 (fr) | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activateur de recepteur active par les proliferateurs du peroxysome |
| WO2002079162A1 (fr) | 2001-03-28 | 2002-10-10 | Eisai Co., Ltd. | Acides carboxyliques |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| EP1394147A4 (de) | 2001-06-04 | 2007-10-24 | Eisai R&D Man Co Ltd | Carbonsäurederivat und eine ein salz oder ein ester davon enthaltende medizin |
| FR2826574B1 (fr) | 2001-06-29 | 2005-08-26 | Oreal | Compositions contenant un derive d'hydroxydiphenyl ether inhibant le developpement des odeurs corporelles |
| DK1424330T3 (da) | 2001-08-10 | 2012-01-16 | Nippon Chemiphar Co | Aktivator for peroxisom proliferator-responsiv receptor delta |
| EP1452521A4 (de) | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | Cyclische verbindung und ppar-agonist |
| CA2460313C (en) | 2001-09-14 | 2011-03-08 | Tularik Inc. | Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
| EP1445258B1 (de) | 2001-10-12 | 2009-06-24 | Nippon Chemiphar Co., Ltd. | Aktivator des peroxisomproliferator-aktivierten rezeptors delta |
| WO2003033453A1 (en) | 2001-10-17 | 2003-04-24 | Novo Nordisk A/S | Dicarboxylic acid derivatives, their preparation and therapeutical use |
| DE10151390A1 (de) | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| JP2003171275A (ja) | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | ＰＰＡＲδアゴニスト |
| US7153878B2 (en) | 2002-02-25 | 2006-12-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| EP1480957A1 (de) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars-aktivatoren |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| WO2004007439A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | ビアリール誘導体 |
| EP1537076A1 (de) | 2002-09-05 | 2005-06-08 | Novo Nordisk A/S | Neue vinylcarbonsäurederivate und ihre therapeutische verwendung |
| AU2003287912A1 (en) * | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
| DE10300099A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| EP1597248B1 (de) | 2003-02-14 | 2007-12-26 | Eli Lilly And Company | Sulfonamid-derivate als ppar-modulatoren |
| US20070105959A1 (en) | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
| TW200510279A (en) | 2003-03-13 | 2005-03-16 | Ono Pharmaceutical Co | Iminoether derivative compound and medicament containing same as active ingredient |
| US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| ATE339205T1 (de) | 2003-04-17 | 2006-10-15 | Kalypsys Inc | (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| CN1812978A (zh) | 2003-04-30 | 2006-08-02 | 药物研发有限责任公司 | 作为蛋白酪氨酸磷酸酶－1b抑制剂的苯基取代羧酸 |
| ES2299906T3 (es) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
| CA2561159A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases |
| CN1956984B (zh) | 2004-04-01 | 2010-06-09 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
| DE602005027677D1 (de) | 2004-04-01 | 2011-06-09 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung |
| BRPI0510024A (pt) | 2004-05-14 | 2007-09-25 | Irm Llc | compostos e composições como modulares de ppar |
| EP2298742B1 (de) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy essigsäuren als PPAR delta Aktivatoren |
| EP1999098A2 (de) * | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung |
-
2005
- 2005-05-03 WO PCT/EP2005/052014 patent/WO2005105726A1/en active Application Filing
- 2005-05-03 US US11/579,712 patent/US7968723B2/en not_active Expired - Fee Related
- 2005-05-03 ES ES05747983T patent/ES2352085T3/es active Active
- 2005-05-03 DE DE602005024384T patent/DE602005024384D1/de active Active
- 2005-05-03 AT AT05747983T patent/ATE486055T1/de not_active IP Right Cessation
- 2005-05-03 JP JP2007512189A patent/JP2007536343A/ja not_active Withdrawn
- 2005-05-03 EP EP05747983A patent/EP1745003B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| ATE486055T1 (de) | 2010-11-15 |
| US7968723B2 (en) | 2011-06-28 |
| EP1745003A1 (de) | 2007-01-24 |
| WO2005105726A1 (en) | 2005-11-10 |
| ES2352085T3 (es) | 2011-02-15 |
| JP2007536343A (ja) | 2007-12-13 |
| EP1745003B1 (de) | 2010-10-27 |
| US20090209588A1 (en) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005024384D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| NO20035526D0 (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| WO2008024390A3 (en) | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| WO2010036613A8 (en) | Novel cyclic benzimidazole derivatives useful anti-diabetic agents | |
| CY1114660T1 (el) | ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1 | |
| WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| ATE555081T1 (de) | Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms | |
| ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| DE602007004324D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| SE0403006D0 (sv) | New compounds | |
| ATE496622T1 (de) | Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten | |
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| RU2010120808A (ru) | Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение | |
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| EA201100007A1 (ru) | Производные хиноксалиндиона | |
| NO20063103L (no) | N-aryl-piperidinsubstituerte bifenyl karboksamider | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| DE602005024539D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| DE602006016323D1 (de) | Oxazol- und thiazol-verbindungen als ppar-modulatoren |